tailieunhanh - Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment

Human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) has a favorable prognosis which has led to efforts to de-intensify treatment. Response-adaptive de-escalated treatment is promising, however improved biomarkers are needed. Quantitative cell-free HPV-DNA (cfHPV-DNA) in plasma represents an attractive non-invasive biomarker for grading treatment response and post-treatment surveillance. | Rosenberg et al. BMC Cancer 2022 22 17 https s12885-021-09146-z STUDY PROTOCOL Open Access Prospective study evaluating dynamic changes of cell free HPV DNA in locoregional viral associated oropharyngeal cancer treated with induction chemotherapy and response adaptive treatment Ari J. Rosenberg1 Evgeny Izumchenko1 Alexander Pearson1 Zhen Gooi2 Elizabeth Blair2 Theodore Karrison3 Aditya Juloori4 Daniel Ginat5 Nicole Cipriani6 Mark Lingen6 Hillary Sloane7 Daniel L. Edelstein7 Kirsten Keyser8 Johannes Fredebohm8 Frank Holtrup8 Frederick S. Jones7 Daniel Haraf4 Nishant Agrawal2 and Everett E. Vokes1 Abstract Background Human papillomavirus HPV -associated oropharyngeal cancer OPC has a favorable prognosis which has led to efforts to de-intensify treatment. Response-adaptive de-escalated treatment is promising however improved biomarkers are needed. Quantitative cell-free HPV-DNA cfHPV-DNA in plasma represents an attractive non-invasive biomarker for grading treatment response and post-treatment surveillance. This prospective study evalu- ates dynamic changes in cfHPV-DNA during induction therapy definitive chemo radiotherapy and post-treatment surveillance in the context of risk and response-adaptive treatment for HPV OPC. Methods Patients with locoregional HPV OPC are stratified into two cohorts High risk HR T4 N3 20 pack-year smoking history PYH or non-HPV16 subtype Low risk LR all other patients . All patients receive induction chemo- therapy with three cycles of carboplatin and paclitaxel. LR with 50 response receive treatment on the single- modality arm minimally-invasive surgery or radiation alone to 50 Gy . HR with 50 response or LR with 30 and Rosenberg et al. BMC Cancer 2022 22 17 Page 2 of 8 Trial registration This trial is registered with on October 1st 2020 with Identifier NCT04 572100. Keywords Head and neck cancer Human papillomavirus Chemotherapy Radiotherapy Treatment de-escalation Background context of concurrent .

• Y khoa - Dược
• BMC Cancer
• Head and neck cancer
• Human papillomavirus
• Treatment de escalation
• Post treatment surveillance
• Oropharyngeal cancer
• Cancer patient pathways
• Colorectal cancer
• Lung cancer
• Breast cancer
• Prostate cancer
• Ovarian cancer
• Cancer detection
• Ovarian cancer symptoms
• Ovarian cancer signs
• Ovarian cancer tests
• Cancer biomarkers
• Pediatric cancer
• Familial cancer predisposition
• Hereditary cancer syndrome
• Genetic cancer susceptibility
• Advanced cancer
• Biliary tract cancer
• Multimodal intervention
• Pancreatic cancer
• Physical activity
• Breast cancer screening
• Familial breast cancer
• Young breast cancer survivors
• High risk relatives
• Randomized trial
• Childhood cancer
• Childhood cancer survivor
• Thyroid cancer screening
• Secondary cancer
• Cancer screening
• Community awareness
• Cancer education
• Cervical cancer
• Prior cancer
• Cancer survivors
• Cancer registry
• Second cancer
• Surgical oncology
• Cancer imaging
• Radiation oncologists
• Medical oncologists
• Oesophagogastric cancer
• Liver cancer
• Hepatobiliary cancer
• Multidisciplinary rehabilitation
• EGFR mutation
• Family history of cancer
• Inherited susceptibility
• Cancer predisposition genes
• Lung cancer aetiology
• Cancer stem cells
• Oct4 overexpressing lung cancer
• Human lung cancer xenograft model
• Disease free survivals
• Cancer hallmarks
• Cancer genesis
• Defiant disease
• Mutational signature
• Cancer diagnosis
• Cancer genomics
• Molecular medicine
• Whole genome sequencing
• Cancer susceptibility gene
• Breast cancer prognosis
• Next generation sequencing
• Quality of care
• Quality indicators
• Shifting cancer care
• German cancer society
• Colorectal cancer screening
• Stomach cancer screening
• Lung cancer survivor
• Physician recommendation
• Total number of lymph nodes
• Lymph node ratio
• Left colon cancer
• Right colon cancer
• Overall survival
• Cumulative incidence
• Esophageal cancer
• Metachronous cancer
• Young onset
• Reproductive cancer
• Risk factor
• Early detection of cancer
• Gastric cancer incidence
• Population based specialized registry
• Gastric cancer survival
• Gastric cancer clinical characteristics
• Gastric cancer pathological characteristics
• Lung Cancer Screening
• Racial disparities
• Lung Cancer diagnosis
• Screening adherence
• Second primary colorectal cancer
• Standardized incidence ratio
• Left sided colon cancer
• Right sided colon cancer
• Quality of cancer care
• Population based study